Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal for Immunotherapy of Cancer|January 29, 2026
Oncolytic peptide LTX-315 targets PD-L1 to improve antitumor immune response of nanosecond pulse electric field in liver cancerKun Ji, Li Jing, Tiantian Xu, et al.
Medicine|June 29, 2018
Comprehensive analysis of common safety profiles and their predictive factors in 520 records of liver cancer patients treated by drug-eluting beads transarterial chemoembolizationJunhui Sun, Guanhui Zhou, Yuelin Zhang, et al.
Academic Radiology|August 27, 2024
Systemic Inflammation-Based Staging System for Hepatocellular Carcinoma After Drug-Eluting Beads Transarterial Chemoembolization: A Multicenter StudyKun Ji, Jiahua Niu, Cong Zhang, et al.
Oncology Research|September 28, 2019
Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres® in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres® Transarterial Chemoembolization in Liver Cancer (CTILC) StudyJunhui Sun, Guanhui Zhou, Xiaoxi Xie, et al.
Medicine|March 21, 2020
Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: A preliminary result from CTILC studyJun Luo, Jiaping Zheng, Changsheng Shi, et al.
Oncology Research|December 21, 2019
The Comprehensive Analysis of Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort StudyZhiyi Peng, Guohong Cao, Qinming Hou, et al.
Translational Cancer Research|February 4, 2022
Efficacy and safety of CalliSpheres® drug-eluting beads transarterial chemoembolization in patients with secondary liver cancer: a preliminary result from CTILC studyXia Wu, Shihong Ying, Jing Huang, et al.
Pageof 2